Pfizer stock after-hours at EUR 24.53: minus 1.92 percent versus prior close
Published on 10/02/2026 at 18:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer stock was at EUR 24.53 in after-hours trading at Lang & Schwarz on October 2, 2026, at 6:45 p.m. CEST. The price was down 1.92 percent versus the Lang & Schwarz prior close of EUR 25.01.
Pfizer stock during Friday’s session
The decline is based on the prior close at Lang & Schwarz. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Pfizer stock.
LITFULO data presented at dermatology congress
Pfizer Inc. said it presented results from two Phase 3 trials evaluating LITFULO, or ritlecitinib, in adults with nonsegmental vitiligo. The company reported that LITFULO significantly improved facial and total-body repigmentation versus placebo at Week 52. In the TRANQUILLO 2 and TRANQUILLO studies, 21.86 percent and 12.47 percent of patients receiving LITFULO achieved F-VASI75, compared with 2.40 percent and 2.48 percent on placebo, respectively.
Regulatory submissions planned
Pfizer said it intends to submit the data to regulators globally, including the U.S. Food and Drug Administration and the European Medicines Agency. The results were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria. Pfizer’s investor-relations newsroom also lists a November 3, 2026, conference call to discuss its third-quarter performance report, which is scheduled for release that morning. Pfizer’s newsroom published the event notice.
